Genetic markers for ovarian cancer risk: are we close to seeing a clinical impact?

ISSN： 1741-0541

Source： Personalized Medicine, Vol.9, Iss.6, 2012-08, pp. : 565-567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thyroid cancer genetics: how close are we to personalizing clinical management?

By Ngeow Joanne Eng Charis

Personalized Medicine, Vol. 9, Iss. 4, 2012-06 ,pp. : 355-358

Future Medicine

Access to resources Recommend Favorite

Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-09 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancer

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3444-3451

John Wiley & Sons Inc

Access to resources Recommend Favorite

The joint impact of prediagnostic inflammatory markers and cardiorespiratory fitness on the risk of cancer mortality

SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS, Vol. 28, Iss. 2, 2018-02 ,pp. : 613-620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combining genetic markers and clinical risk factors improves the risk assessment of impaired glucose metabolism

By Ruchat Stephanie-May Vohl Marie-Claude Weisnagel S. John Rankinen Tuomo Bouchard Claude Pérusse Louis

Annals of Medicine, Vol. 42, Iss. 3, 2010-04 ,pp. : 196-206

Informa Healthcare

Access to resources Recommend Favorite